Abstract
Introduction
Dysfibrinogenemia is a disorder of fibrinogen structure and is associated with a functional abnormality. Since fibrinogen is a key component of both the procoagulant and fibrinolytic pathways, defects in fibrinogen function can be associated with increased risk for both hemorrhage and thrombosis. Management of patients with dysfibrinogenemia and a thrombotic tendency usually involves long-term anticoagulation.
Case
A 36-year-old male with relapsed nodular sclerosing Hodgkin’s was found to have a prolonged prothrombin time, low fibrinogen activity and a normal fibrinogen antigen during evaluation for a hematopoietic peripheral blood stem cell transplant. His past medical history was significant for an acute myocardial infarction and two episodes of acute pancreatitis. His father had dysfibrinogenemia complicated by multiple thrombotic episodes. A trans-esophageal echocardiogram revealed two thrombi, one each in the superior vena cava and the descending aorta. He was treated with enoxaparin and received peripheral blood stem cell transplantation. An effort was made to maintain his fibrinogen activity levels at 200 mg/dL using cryoprecipitate. A month following the transplant he developed a new thrombus in the right internal jugular vein, while on enoxaparin and he was started on argatroban and cryoprecipitate followed by fondaparinux. A repeat echocardiogram six weeks later demonstrated that the burden of thrombus both in the right atrium and descending aorta was significantly lower.
Discussion
This is the first case report of a patient with dysfibrinogenemia undergoing peripheral blood stem cell transplantation. Conventional anticoagulant therapy and cryoprecipitate seem to be a reasonable management strategy to prevent thrombosis in a patient with dysfibrinogenemia and a thrombophilic tendency. Secondly, fondaparinux can be used in cases of failure of therapy with low molecular weight heparins and may actually be superior to low molecular weight heparins, especially in patients with dysfibrinogenemia.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Hayes T (2002) Dysfibrinogenemia and thrombosis. Arch Pathol Lab Med 126:1387–1390
Haverkate F, Samama M (1995) Familial dysfibrinogenemia and thrombophilia: report on a study of the SCC subcommittee on fibrinogen. Thromb Haemost 73:151–161
McDonagh J (2001). Dysfibrinogenemia and other disorders of fibrinogen structure or function. In: Colman R, Hirsh J, Marder V, Clowes A, George J (eds) Hemostasis and Thrombosis, 4th edn. Lippincott Williams & Wilkins, Philadelphia, PA, pp 855–892
Ebert R (1994) Index of variant human fibrinogens. CRC Press, Boca Raton, FL
Mosesson M (1999) Dysfibrinogenemia and thrombosis. Semin Thromb Hemost 25:311–319
Hamano A, Mimuro J, Aoshima M, Itoh T, Kitamura N, Nishinarita S, Takano K, Ishiwata A, Kashiwakura Y, Niwa K, Ono T, Madoiwa S, Sugo T, Matsuda M, Sakata Y (2004) Thrombophilic dysfibrinogen Tokyo V with the amino acid substitution of gammaAla327Thr: formation of fragile but fibrinolysis-resistant fibrin clots and its relevance to arterial thromboembolism. Blood 103:3045–3050
Benson DW, Sharkey A, Fatkin D, Lang P, Basson CT, McDonough B, Strauss AW, Seidman JG, Seidman CE (1998) Reduced penetrance, variable expressivity, and genetic heterogeneity of familial atrial septal defects. Circulation 97:2043–2048
Weitz JI (1997) Low-molecular weight heparin. N Engl J Med 337:688–698
Ahmed S, Karim A, Patel D, Siddiqui R, Mattana J (2002) Low-molecular weight heparin: treatment failure in a patient with primary antiphospholipid antibody syndrome. Am J Med Sci 324:279–280
Bowdish ME, Weaver FA, Liebman HA, Rowe VL, Hood DB (2002) Anticoagulation is an effective treatment for aortic mural thrombi. J Vasc Surg 36:713–719
Takala T, Oksa H, Rasi V, Tuimala R (1991) Dysfibrinogenemia associated with thrombosis and third-trimester fetal loss. A case report. J Reprod Med 36:410–412
Edwards RZ, Rijhsinghani A (2000) Dysfibrinogenemia and placental abruption. Obstet Gynecol 95:1043
Yamanaka Y, Takeuchi K, Sugimoto M, Sato A, Nakago S, Maruo T (2003) Dysfibrinogenemia during pregnancy treated successfully with fibrinogen. Acta Obstet Gynecol Scand 82:972–973
al-Fawaz IM, Gader AM (1992) Severe congenital dysfibrinogenemia (fibrinogen-Riyadh): a family study. Acta Haematol 88:194–197
Mannucci PM, Duga S, Peyvandi F (2004) Recessively inherited coagulation disorders. Blood 104:1243–1252
Reynolds NA, Perry CM, Scott LJ (2004) Fondaparinux sodium: a review of its use in the prevention of venous thromboembolism following major orthopaedic surgery. Drugs 64:1575–1596
Turpie AG, Bauer KA, Eriksson BI, Lassen MR (2004) Superiority of fondaparinux over enoxaparin in preventing venous thromboembolism in major orthopedic surgery using different efficacy end points. Chest 126:501–508
Büller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, Prins MH, Raskob G, Segers AE, Cariou R, Leeuwenkamp O, Lensing AWA The Matisse Investigators (2004) Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med 140:867–873
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ganti, A.K., Vose, J.M. & Haire, W.D. Hematopoietic stem cell transplantation for Hodgkin’s disease in a patient with dysfibrinogenemia and thrombosis. J Thromb Thrombolysis 23, 155–158 (2007). https://doi.org/10.1007/s11239-006-9037-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11239-006-9037-0